NRX Pharmaceuticals Inc (NASDAQ: NRXP) Announces the Beginning of Crisis use Exercise and Addition of Phase 2/3 Inhaled ZYESAMI™ Pilot in Georgia

July 24, 2021

NRX Pharmaceuticals Inc (NASDAQ: NRXP) announced it is starting scientific training of Nation of Georgia (Georgia) ICU doctors in the use of circulatory ZYESAMI™ for crisis use in patients suffering from Acute COVID-19, and gasped ZYESAMI™ for usage in phase 2/3 scientific trials, for patients in sorrow with COVID-19. NRx lengthens its unending Phase 2/3 pilot of gasped ZYESAMI™ to Georgia NRx also announced that the continuing stage 2/3 pilot…


Relief Therapeutics Inc.’s (OTCMKTS: RLFTF) Partner, NRx Pharmaceuticals Inc. (NASDAQ: NRXP), Studying Aviptadil In COVID-19 Treatment

July 14, 2021

Relief Therapeutics Inc. (OTCMKTS: RLFTF) has announced that NRx Pharmaceuticals Inc. (NASDAQ: NRXP), its collaboration partner, and Quantum Leap Healthcare Collaborative have commenced patient treatment with inhaled Aviptadil in phase 2 adaptive platform trial, I-SPY COVID Trial, in enhancing treatment for critically and severely ill SARS-CoV-2 patients.  Relief Therapeutics’ flagship drug candidate evaluated for COVID-19 treatment  The company develops molecules-based clinical-stage programs with historical clinical testing and use for human…